Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 38.81 USD 2.51% Market Closed
Market Cap: 3.2B USD
Have any thoughts about
Verona Pharma PLC?
Write Note

Verona Pharma PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Verona Pharma PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Verona Pharma PLC
NASDAQ:VRNA
Revenue
$5.6m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Revenue
ÂŁ31.4B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Revenue
$49.1B
CAGR 3-Years
18%
CAGR 5-Years
16%
CAGR 10-Years
6%
Indivior PLC
LSE:INDV
Revenue
$1.1B
CAGR 3-Years
17%
CAGR 5-Years
4%
CAGR 10-Years
0%
Hikma Pharmaceuticals PLC
LSE:HIK
Revenue
$3B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
7%
Dechra Pharmaceuticals PLC
LSE:DPH
Revenue
ÂŁ761.5m
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
15%
No Stocks Found

Verona Pharma PLC
Glance View

Market Cap
3.2B USD
Industry
Pharmaceuticals

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The firm is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The company is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.

VRNA Intrinsic Value
15.98 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

What is Verona Pharma PLC's Revenue?
Revenue
5.6m USD

Based on the financial report for Sep 30, 2024, Verona Pharma PLC's Revenue amounts to 5.6m USD.

What is Verona Pharma PLC's Revenue growth rate?
Revenue CAGR 3Y
-48%

Over the last year, the Revenue growth was 1 123%. The average annual Revenue growth rates for Verona Pharma PLC have been -48% over the past three years .

Back to Top